Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review.
作者： Ioan Sporea , Roxana Sirli , Simona Bota , Alina Popescu , Mihnea Strain
DOI:
关键词:
摘要: BACKGROUND Patients with HCV liver cirrhosis are a category difficult to treat. The aim of this study was establish the sustained virological response (SVR) rates in patients treated standard care therapy (Pegylated Interferon and Ribavirin for 48 weeks genotypes 1 4 24 2 3). METHODS Searching PubMed, Medline, Lilacs, Scopus, Ovid Medscape databases we identified all articles published until February 2011 that included only cirrhotic patients. These studies evaluated SVR after treatment: Pegylated alpha 2a (doses ranging between 135-180 µg/week) or 2b (1 1.5 µg/kg/week) 800-1200 mg/day). We used following key words: HCV, cirrhosis, (SVR). RESULTS overall rate 33.3% (95%CI-confidence interval=30.6-36.2%). significantly higher 3 (422 patients) as compared those (692 patients): 55.4% (95%CI=50.7-60.1) versus 21.7% (95%CI=18.7-25), p < 0.0001. CONCLUSION is 33.3%, but lower cases affected by (21.6%) which makes them priority regarding development more potent drugs effective treatment.
参考文章(35)
Stefan Zeuzem, John M. Vierling, Rafael Esteban, Alexandra L. Gibas, Stanislas Pol, Navdeep Boparai, Margaret Burroughs, Clifford A. Brass, Janice K. Albrecht, Fred Poordad, Predictors of Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin Gastroenterology. ,vol. 140, pp. S- 908 ,(2011) , 10.1016/S0016-5085(11)63771-2
Khalid Mumtaz, Wasim Jafri, Hasnain A Shah, Irum Aqeel, Saeed Hamid, Amna Subhan Butt, Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis. Tropical gastroenterology : official journal of the Digestive Diseases Foundation. ,vol. 30, pp. 207- ,(2009)
Fred Poordad, Jean-Pierre Bronowicki, Stuart C. Gordon, Stefan Zeuzem, Ira M. Jacobson, Mark Sulkowski, Thierry Poynard, Timothy R. Morgan, Margaret Burroughs, Vilma Sniukiene, Navdeep Boparai, Clifford A. Brass, Janice K. Albrecht, Bruce R. Bacon, IL28B Polymorphism Predicts Virologic Response in Patients With Hepatitis C Genotype 1 Treated With Boceprevir (Boc) Combination Therapy Gastroenterology. ,vol. 140, pp. S- 941 ,(2011) , 10.1016/S0016-5085(11)63904-8
G.M. Dusheiko, M.W. Fried, R. Reddy, D.R. Nelson, N. Bzowej, N. Adda, C.I. Wright, L. Bengtsson, S. George, S.L. Flamm, 415 TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN INCREASED SUSTAINED VIROLOGIC RESPONSE RATES IN TREATMENT-NAIVE PATIENTS REGARDLESS OF RACE OR ETHNICITY Journal of Hepatology. ,vol. 54, ,(2011) , 10.1016/S0168-8278(11)60417-0
Marina Berenguer, Martín Prieto, Fernando San Juan, José M. Rayón, Fernando Martinez, Domingo Carrasco, Angel Moya, Francisco Orbis, José Mir, Joaquín Berenguer, Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology. ,vol. 36, pp. 202- 210 ,(2002) , 10.1053/JHEP.2002.33993
Edward Gane, The natural history and outcome of liver transplantation in hepatitis C virus‐infected recipients Liver Transplantation. ,vol. 9, ,(2003) , 10.1053/JLTS.2003.50248
Ke-Qin Hu, Myron J. Tong, The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. ,vol. 29, pp. 1311- 1316 ,(1999) , 10.1002/HEP.510290424
Wolf Peter Hofmann, Stefan Zeuzem, A new standard of care for the treatment of chronic HCV infection Nature Reviews Gastroenterology & Hepatology. ,vol. 8, pp. 257- 264 ,(2011) , 10.1038/NRGASTRO.2011.49
Andri Rauch, Zoltán Kutalik, Patrick Descombes, Tao Cai, Julia Di Iulio, Tobias Mueller, Murielle Bochud, Manuel Battegay, Enos Bernasconi, Jan Borovicka, Sara Colombo, Andreas Cerny, Jean–François Dufour, Hansjakob Furrer, Huldrych F. Günthard, Markus Heim, Bernard Hirschel, Raffaele Malinverni, Darius Moradpour, Beat Müllhaupt, Andrea Witteck, Jacques S. Beckmann, Thomas Berg, Sven Bergmann, Francesco Negro, Amalio Telenti, Pierre–Yves Bochud, Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study Gastroenterology. ,vol. 138, pp. 1338- 1345 ,(2010) , 10.1053/J.GASTRO.2009.12.056
Sammy Saab, Douglas R. Hunt, Michael A. Stone, Amy McClune, Myron J. Tong, Timing of hepatitis C antiviral therapy in patients with advanced liver disease: A decision analysis model Liver Transplantation. ,vol. 16, pp. NA- NA ,(2010) , 10.1002/LT.22072